Interferon beta in the treatment of multiple sclerosis: Mechanisms of action

V. Wee Yong; Sophie Chabot; Olaf Stuve; Gary Williams

Interferon beta in the treatment of multiple sclerosis: Mechanisms of action

V. Wee Yong, Sophie Chabot, Olaf Stuve, Gary Williams

Research output: Contribution to journal › Review article › peer-review

Abstract

Interferon beta (IFN-β) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-β are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-β may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-β can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-β in MS.

Original language	English (US)
Pages (from-to)	682-689
Number of pages	8
Journal	Neurology
Volume	51
Issue number	3
State	Published - Sep 1 1998

ASJC Scopus subject areas

Clinical Neurology

Fingerprint Dive into the research topics of 'Interferon beta in the treatment of multiple sclerosis: Mechanisms of action'. Together they form a unique fingerprint.

Cite this

@article{b01bec7eead24e7f979be57b8e528917,

title = "Interferon beta in the treatment of multiple sclerosis: Mechanisms of action",

abstract = "Interferon beta (IFN-β) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-β are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-β may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-β can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-β in MS.",

author = "Yong, {V. Wee} and Sophie Chabot and Olaf Stuve and Gary Williams",

year = "1998",

month = sep,

day = "1",

language = "English (US)",

volume = "51",

pages = "682--689",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Interferon beta in the treatment of multiple sclerosis

T2 - Mechanisms of action

AU - Yong, V. Wee

AU - Chabot, Sophie

AU - Stuve, Olaf

AU - Williams, Gary

PY - 1998/9/1

Y1 - 1998/9/1

N2 - Interferon beta (IFN-β) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-β are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-β may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-β can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-β in MS.

AB - Interferon beta (IFN-β) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-β are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-β may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-β can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-β in MS.

UR - http://www.scopus.com/inward/record.url?scp=0008376732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0008376732&partnerID=8YFLogxK

M3 - Review article

C2 - 9748010

AN - SCOPUS:0008376732

VL - 51

SP - 682

EP - 689

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -